Multicenter comparison of cefotetan and cefoxitin in the treatment of acute obstetric and gynecologic infections.
Two hundred eighty-seven women were treated in a multicenter, randomized, comparative study to compare the safety and efficacy of cefotetan every 12 hours with that of cefoxitin every 6 or 8 hours in the treatment of acute obstetric and gynecologic pelvic infections. The most frequent primary diagnoses in both groups were endometritis and pelvic inflammatory disease; 24 of these patients were also bacteremic. The mean duration of treatment was 5.2 and 5.4 days for the cefotetan and cefoxitin groups, respectively, and the total doses administered were 18.1 and 32.1 gm, respectively. The rate of clinical failure for the cefotetan group was 8.5% and 12.2% for the cefoxitin group. Laboratory and clinical adverse reactions were infrequent and none was serious; both antimicrobials were well tolerated. These results suggest the administration of cefotetan provided adequate clinical and bacteriologic effectiveness in the treatment of hospital- and community-acquired, polymicrobial obstetric and gynecologic pelvic infections.
Hemsell
D L
DL
Division of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas 75235.
Wendel
G D
GD
Gall
S A
SA
Newton
E R
ER
Gibbs
R S
RS
Knuppel
R A
RA
Lane
T W
TW
Sweet
R L
RL
D000208:Acute Disease; D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy*; D015313:Cefotetan; D002440:Cefoxitin / Q000627:therapeutic use*; D002513:Cephamycins / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003428:Cross Infection / Q000188:drug therapy; D004716:Endometritis / Q000188:drug therapy; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy*; D006801:Humans; D000292:Pelvic Inflammatory Disease / Q000188:drug therapy; D011897:Random Allocation
D002513:Cephamycins; D015313:Cefotetan; D002440:Cefoxitin